Abstract:Objective To investigate the clinical effect of the treatment of children with hand foot and mouth disease by the combination of ShuFeng Jiedu Capsules and Ribavirin.Methods 60 patients from December 2014 to December 2015 in our hospital with pediatric clinical diagnosis of hand,foot and mouth disease in children with of general type were selected,according to the random number method,were randomly divided into two groups.The conventional treatment group(the control group)was treated with Ribavirin Injection,and the treatment group(observation group)was treated with Ribavirin combined with Shufeng Jiedu Capsules after treatment 5 days,and the patients were followed up for 3 days after the treatment.The children with rash subsided,oral herpes subsided time and cooling time of two groups were compared.Results After the treatment,the rash subsided time of observation group was(2.52±0.26)days,the control group was(4.01±0.57)days,the observation group was significantly shorter than that of control group,the difference was significant(P<0.05);the blebsubsidise time of observation group was(2.31±0.31)days,the control group was(3.46±0.57) days,the observation group was significantly shorter than that of control group,the difference was significant(P<0.05);after treatment,the observation group body temperature was(36.8±0.5)℃,the control group was(37.5±0.5)℃,the difference was significant(P<0.05);the cooling time of observation group was(2.2±1.1)days,the control group was(4.3±1.4)days, the observation group was significantly shorter than that of control group,the difference was significant(P<0.05).Conclusion Shufeng Jiedu Capsules combined with Ribavirin has better clinical efficacy in the treatment of children with hand foot and mouth disease,it is worthy of promotion.
张文忠. 疏风解毒胶囊联合利巴韦林治疗手足口病的临床效果观察[J]. 中国当代医药, 2016, 23(31): 110-112.
ZHANG Wen-zhong. Clinical effect observation on the treatment of hand foot and mouth disease with the combination of the Shufeng Jiedu Capsules and Ribavirin. 中国当代医药, 2016, 23(31): 110-112.